The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of EP-100, a luteinizing hormone releasing hormone (LHRH) ligand conjugated to a synthetic cytolytic peptide in patients with advanced refractory LHRH- receptor (R)-expressing tumors.
Ramesh K. Ramanathan
Research Funding - Esperance Pharmaceuticals
Manpreet Chadha
No relevant relationships to disclose
John Sarantopoulos
Research Funding - Esserance Pharmaceuticals
Donald W. Northfelt
No relevant relationships to disclose
Glen J. Weiss
No relevant relationships to disclose
Monica M. Mita
Research Funding - Esperance Pharmaceuticals
Kerry M. Barnhart
Consultant or Advisory Role - Esperance Pharmaceuticals
John Whisnant
Employment or Leadership Position - Esperance Pharmaceuticals
Consultant or Advisory Role - Esperance Pharmaceuticals
Carola Leuschner
Employment or Leadership Position - Esperance Pharmaceuticals
Stock Ownership - Esperance Pharmaceuticals
Hector Alila
Employment or Leadership Position - Esperance Pharmaceuticals
Stock Ownership - Esperance Pharmaceuticals
Kelly Kevelin Curtis
Research Funding - Esperance Pharmaceuticals